Browse News
Filter News
Found 9,561 articles
-
Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.
-
Mayank Mamtani, managing director and group head of healthcare research at B. Riley Securities, told BioSpace he believes Altimmune's pemvidutide still shows promise despite safety concerns.
-
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
3/22/2023
Flare Therapeutics Inc. announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest and Third Rock Ventures and new investors Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital and ShangBay Capital.
-
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
3/20/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 – April 1, 2023.
-
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023
3/20/2023
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), Pemazyre® (pemigatinib) and IBI351 (KRASG12C inhibitor) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, April 14 - 19, 2023.
-
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
3/16/2023
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update.
-
Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.
-
Weeks after the FDA rejected Veru’s Emergency Use Authorization bid for sabizabulin in COVID-19, the company announced plans to continue with late-stage development of the drug.
-
After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.
-
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
3/15/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today provides an update on a decision by the Opposition Division of the European Patent Office ("EPO") regarding one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC.
-
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
3/15/2023
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old.
-
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
3/15/2023
Dermavant Sciences today announced positive results from ADORING 2, one of two double-blind, randomized, vehicle-controlled Phase 3 studies to evaluate the efficacy and safety of topical VTAMA® (tapinarof) cream, 1% in pediatric subjects down to 2 years old and adult subjects with atopic dermatitis (AD).
-
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
3/15/2023
Mediar Therapeutics Inc. announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures.
-
Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.
-
Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology
3/14/2023
Switch Therapeutics today announced its launch following $52 million of financing.
-
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
3/14/2023
Sigilon Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 as well as certain other business highlights.
-
Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
3/14/2023
Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 – 19, 2023.
-
Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing
3/10/2023
Allorion Therapeutics ("Allorion"), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a $50 million Series B financing round.
-
Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease.
-
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
3/9/2023
Sermonix anticipates dosing the first patient in first half of 2023.